Café

© 2026 Longbridge｜Terms of Service Privacy Policy

LTRN

LTRN

2.1109.83%( -0.230 )

LongbridgeAI

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News

StockTitan

Jun 1, 2026 at 11:15 PM

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News

Login to unlock170characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Lantern Pharma

LTRN.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--